Clinical Guidelines
Feature

Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer

Share

Metastatic triple-positive breast cancer presents a complex challenge in treatment, comprising HR+ and HER2+ characteristics that demand multimodal therapeutic approaches. During JADPRO Live 2025, experts Danielle Roman and Kaitlyn Reeder highlighted pivotal clinical trials and the latest therapy guidelines, emphasizing early toxicities management. The declining survival rates in metastatic cases prompt the usage of advanced treatments including dual HER2 blockade, chemotherapy, and emerging agents like trastuzumab deruxtecan, alongside the critical importance of monitoring and addressing adverse events effectively.

Original Source(s)

Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer

  • by Danielle Roman, PharmD, BCOP, Kaitlyn Reeder, PA-C

  • February 27, 2026

  • 8 min

Related Content

New Collaboration to Automate Cell Therapy Manufacturing with Robotics

Focus on scaling cell therapy manufacturing using GMP-ready end-to-end robotic biomanufacturing technology

  • February 12, 2026

  • 2 min
Overcoming the Challenges of AI Antibody Analysis

Cracking the molecular code

Three Dana-Farber Cancer Institute scientific leaders elected as Fellows of the American Association for Cancer Research (AACR) Academy Class of 2026

Dr. Alice Shaw, Dr. Kimberly Stegmaier and Dr. Matthew Vander Heiden have been elected as Fellows of the American Association for Cancer Research (AACR) Academy Class of 2026.

  • by

  • February 3, 2026

  • 3 min